AstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...

In addition to its indications in lung cancers, IMFINZI is approved in combination with chemotherapy (gemcitabine plus cisplatin) in locally advanced or metastatic biliary tract cancer and in ...

driven by demand growth across all approved indications. Imfinzi is being evaluated for multiple cancers, either alone or in combination with other regimens, including phase III studies in earlier ...

Imfinzi was first approved for treating bladder cancer in 2017. Its label was later expanded to include more indications including unresectable NSCLC, small-cell lung cancer, metastatic NSCLC ...

(Alliance News) - AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free ...

Imfinzi is already approved for unresectable ... Sales momentum for the drug is still good, however, fuelled by a lengthening list of indications in other cancers, including most recently primary ...

Immune checkpoint blockade involves drugs that we call PD-1 or PDL-1 inhibitors, and Imfinzi is a PDL-1 inhibitor. These drugs have been used alone in various indications and also combined with ...

It's a disappointing result for AZ, which is trying to extend the uses of Imfinzi from its current approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC ...

Several other label expansion studies on Imfinzi are currently underway, targeting other cancer indications. Imfinzi remains a key revenue driver for AstraZeneca’s oncology portfolio.